Walking speed,rather than Expanded Disability Status Scale,relates to long-term patient-reported impact in progressive MS

Abstract

Objective:

To study the relationships between 1–2 year changes in well-known physician-rated measurements (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT)) and the long-term (≥ 5 years) outcome in patient-reported outcome (PRO) measures (Multiple Sclerosis Impact Scale (MSIS-29), Multiple Sclerosis Walking Scale (MSWS-12)) that reflect the patient-perceived impact of disease, in progressive MS.

Methods:

We selected all progressive patients having at least two complete visits within 1-2 years, from a larger cohort of prospectively-followed MS patients. These were invited for another visit, at least 5 years later, consisting of another series of similar examinations, plus 2 PRO scales: the MSIS-29 and MSWS-12. We explored associations between early changes in physician-rated measurements and the long-term outcome as per the PRO measures.

Results:

In this study,134 patients fulfilled the selection criteria. We found that early change in T25FW was the only physician-rated change that was significantly related to long-term physical impact experienced by the patient, as was assessed by MSIS-29 (Kruskal-Wallis test: χ²=7.8, p=0.020). Early T25FW change, and to a lesser degree early 9HPT change, were significantly related to the reported long-term walking limitations, as assessed by MSWS-12 (Kruskal-Wallis test: χ²=13.8 and p=0.001 for T25FW, χ²=6.5 and p=0.038 for 9HPT). None of the early physician-rated changes were related to the long-term psychological impact experienced by the patient.

Conclusion:

Early changes on physician-rated scales do have long-term impact in terms of potentially predictive value of outcomes for groups of patients in progressive MS, regarding walking limitations and more global physical impact. Surprisingly, early change in T25FW, rather than early change in EDSS, was significantly associated with longer-term patient-reported disease impact. Our study data support the value of using early physician-rated examinations in clinical trials in progressive MS.

Keywords

Multiple sclerosis progressive MS Timed 25-Foot Walk Expanded Disability Status Scale clinical outcome patient-reported outcome PRO scales prognosis long-term outcome indicators of progression

Get full access to this article

View all access options for this article.

References

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurol 1983; 33: 1444–1552.

Hobart

Freeman

Thompson

. Kurtzke scales revisited: The application of psychometric methods to clinical intuition. Brain 2000; 123: 1027–1040.

Sharrack

Hughes

Soudain

. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122: 141–159.

Cutter

Baier

Rudick

. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871–882.

Department of Health and Human Services, Food and Drug Administration. Guidance for industry, patient-reported outcome measures: Use in medical product development to support labelling claims, www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (2009, accessed 25 October, 2011).

Hobart

Lamping

Fitzpatrick

. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001; 124: 962–973.

Hobart

Riazi

Lamping

. Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurol 2003; 60: 31–36.

Scalfari

Neuhaus

Degenhardt

. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133: 1914–1929.

Heesen

Bohm

Reich

. Patient perception of bodily functions in multiple sclerosis: Gait and visual function are the most valuable. Mult Scler 2008; 14: 988–991.

10.

Lublin

Reingold

. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurol 1996; 46: 907–911.

11.

Poser

Paty

Scheinberg

. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

12.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005; 58: 840–846.

13.

Lechner-Scott

Kappos

Hofman

. Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler 2003; 9: 154–159.

14.

Hoogervorst

Zwemmer

Jelles

. Multiple Sclerosis Impact Scale (MSIS-29): Relation to established measures of impairment and disability. Mult Scler 2004; 10: 569–574.

15.

Kalkers

De Groot

Lazeron

. MS functional composite: Relation to disease phenotype and disability strata. Neurol 2000; 54: 1233–1239.

16.

Hobart

Riazi

Lamping

. Improving the evaluation of therapeutic interventions in multiple sclerosis: Development of a patient-based measure of outcome. Health Technol Assess 2004; 8: iii,1–48.

17.

Kragt

Thompson

Montalban

. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurol 2008; 70: 1084–1091.

18.

Kremenchutzky

Rice

Baskerville

. The natural history of multiple sclerosis: A geographically based study 9: Observations on the progressive phase of the disease. Brain 2006; 129: 584–594.

19.

Bosma

Kragt

Brieva

. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler 2009; 15: 715–720.